EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Bruce E. Sands  ¹     Krisztina Barbara Gecse  ²     David T. Rubin  ³     Yvette Leung  ⁴     Julian Panés  ⁵     Martina Goetsch  ⁶     Wenjin Wang  ⁷     Kevin Shan  ⁸     John C. Woolcott  ⁸     Christina Smith  ⁸     Karolina Wosik  ⁹     Stefan Schreiber  ^10    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Amsterdam University Medical Center, Amsterdam, Netherlands
³ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
⁴ University of British Columbia, Vancouver, Canada
⁵ Formerly of Hospital Clínic Barcelona, IDIBAPS, CIBRehd, Barcelona, Spain
⁶ Pfizer AG, Zürich, Switzerland
⁷ Pfizer Inc, Collegeville, United States
⁸ Pfizer Inc, New York, United States
⁹ Pfizer Inc, Kirkland, Canada
¹⁰ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)